Provided by Tiger Fintech (Singapore) Pte. Ltd.

Scilex Holding Company

22.17
-0.6300-2.76%
Volume:239.68K
Turnover:5.46M
Market Cap:154.21M
PE:-1.57
High:23.91
Open:22.75
Low:22.00
Close:22.80
52wk High:41.30
52wk Low:3.60
Shares:6.96M
Float Shares:5.41M
Volume Ratio:1.62
T/O Rate:4.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.1311
EPS(LYR):-19.4321
ROE:--
ROA:-65.79%
PB:-0.62
PE(LYR):-1.14

Loading ...

Company Profile

Company Name:
Scilex Holding Company
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
31
Office Location:
960 San Antonio Road,Palo Alto,California,United States
Zip Code:
94303
Fax:
- -
Introduction:
Scilex Holding Company, a biopharmaceutical company, focuses on acquiring, developing, and commercializing non-opioid management products for the treatment of acute and chronic pain. It offers ZTlido, a prescription lidocaine topical product for the relief of neuropathic pain related with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also develops SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trial for the treatment of low back pain; and SP-104 (4.5 mg), a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Directors

Name
Position
Henry Ji
Executive Chairperson,Chief Executive Officer,President and Director
Annu Navani
Director
Dorman Followwill
Director
Jaisim Shah
Director
Jay Chun
Director
Yue Alexander Wu
Director

Shareholders

Name
Position
Henry Ji
Executive Chairperson,Chief Executive Officer,President and Director
Stephen Ma
Chief Financial Officer, Senior Vice President and Secretary